Health Trials

KRAS-mutated

1

Review clinical trials related to KRAS-mutated. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner

Participants needed: 48
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Updated: May 1, 2026Locations: 1
Eligibility criteria

aged between ≥ 18 years and ≤75 years; regardless of male or female. [+3]

Prior treatment with MEK inhibitors、anlotinib or other VEGFR-TKI(such as cabozan... [+6]

Read more